• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Kenvue Inc.

    5/12/25 10:32:18 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary
    Get the next $KVUE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    KENVUE INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    49177J102

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    49177J102


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    64,876,232.68
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    113,995,514.06
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    113,995,514.06
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    49177J102


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    113,995,514.06
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    113,995,514.06
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    KENVUE INC
    (b)Address of issuer's principal executive offices:

    199 GRANDVIEW ROAD,SKILLMAN,NJ,US,08558
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    49177J102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    113995514.06
    (b)Percent of class:

    6.0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    113995514.06

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of KENVUE INC. No one other person's interest in the COMMON STOCK of KENVUE INC is more than five percent of the total outstanding COMMON STOCK.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:05/09/2025
     
    Abigail P. Johnson
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
    Date:05/09/2025

    Comments accompanying signature:  * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003.** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $KVUE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KVUE

    DatePrice TargetRatingAnalyst
    4/10/2025$23.50Neutral
    Redburn Atlantic
    3/24/2025$25.00In-line
    Evercore ISI
    1/6/2025$21.00 → $26.00Neutral → Overweight
    Piper Sandler
    12/12/2024$25.00 → $24.00Buy → Hold
    Deutsche Bank
    9/24/2024$27.00Buy
    Jefferies
    9/24/2024$24.00Outperform → Sector Perform
    RBC Capital Mkts
    5/28/2024$21.00Neutral
    Citigroup
    4/11/2024$18.00Underperform
    Bernstein
    More analyst ratings

    $KVUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Everyday Care in Action: Thousands of Kenvue Employees Come Together Across 21 Markets to Help Advance Healthier Communities

      Kenvuers contribute 5,000+ hours of volunteer time to local causes along with building 22,000+ hygiene kits for underserved communities Hygiene kits to feature 110,000+ donated products from iconic brands Neutrogena®, Listerine®, OGX®, Johnson's® Baby and more Kenvue Inc. (NYSE:KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced its global community engagement efforts in celebration of Kenvue Cares Week, the company's signature annual volunteer initiative part of its Healthy Lives Mission. Kenvue Cares Week is a testament to the strong Kenvue commitment to advance the well-being of people and our planet, giving back through voluntee

      5/14/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Reports First Quarter 2025 Results

      Net Sales (3.9)%; Organic Sales1 (1.2)% Maintains Focus On Accelerating Profitable Growth and Optimizing Cost Structure, While Successfully Completing TSA Exits Updates Outlook for FY'25 for Incremental Tariff Costs and Currency Kenvue Inc. (NYSE:KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment," said Thibaut Mongon, Chief Executive Officer. "We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable profitable growth." First Quarter Summary Net sales decreased 3.9% vs the prior year p

      5/8/25 6:50:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Announces Chief Financial Officer Transition

      Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

      5/8/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Kenvue with a new price target

      Redburn Atlantic initiated coverage of Kenvue with a rating of Neutral and set a new price target of $23.50

      4/10/25 12:41:58 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Evercore ISI initiated coverage on Kenvue with a new price target

      Evercore ISI initiated coverage of Kenvue with a rating of In-line and set a new price target of $25.00

      3/24/25 8:39:49 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Kenvue from Neutral to Overweight and set a new price target of $26.00 from $21.00 previously

      1/6/25 8:13:28 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Smith Jeffrey C disposed of 1,124,062 shares (SEC Form 4)

      4 - Kenvue Inc. (0001944048) (Issuer)

      5/16/25 9:32:14 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 3 filed by new insider Banati Amit

      3 - Kenvue Inc. (0001944048) (Issuer)

      5/16/25 4:41:26 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Director Smith Jeffrey C

      4 - Kenvue Inc. (0001944048) (Issuer)

      4/2/25 4:36:01 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Kenvue Inc.

      SCHEDULE 13G/A - Kenvue Inc. (0001944048) (Subject)

      5/14/25 10:45:26 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Amendment: SEC Form SCHEDULE 13G/A filed by Kenvue Inc.

      SCHEDULE 13G/A - Kenvue Inc. (0001944048) (Subject)

      5/12/25 10:32:18 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 10-Q filed by Kenvue Inc.

      10-Q - Kenvue Inc. (0001944048) (Filer)

      5/8/25 4:04:23 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

      SC 13G/A - Kenvue Inc. (0001944048) (Subject)

      11/14/24 1:22:40 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

      SC 13G/A - Kenvue Inc. (0001944048) (Subject)

      11/12/24 10:32:12 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

      SC 13G/A - Kenvue Inc. (0001944048) (Subject)

      10/16/24 10:07:52 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Financials

    Live finance-specific insights

    See more
    • Kenvue Reports First Quarter 2025 Results

      Net Sales (3.9)%; Organic Sales1 (1.2)% Maintains Focus On Accelerating Profitable Growth and Optimizing Cost Structure, While Successfully Completing TSA Exits Updates Outlook for FY'25 for Incremental Tariff Costs and Currency Kenvue Inc. (NYSE:KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment," said Thibaut Mongon, Chief Executive Officer. "We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable profitable growth." First Quarter Summary Net sales decreased 3.9% vs the prior year p

      5/8/25 6:50:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue to Announce First Quarter 2025 Results on May 8, 2025

      Kenvue Inc. (NYSE:KVUE) will announce its first quarter 2025 financial results before market open on May 8, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine

      4/24/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Declares Quarterly Cash Dividend

      Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on its common stock. This quarterly dividend is payable on May 28, 2025, to shareholders of record as of the close of business on May 14, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in

      4/16/25 8:19:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Leadership Updates

    Live Leadership Updates

    See more
    • Kenvue Announces Chief Financial Officer Transition

      Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

      5/8/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Announces Three New Appointments to Board of Directors

      Company and Starboard Value LP Enter into Cooperation Agreement Kenvue Inc. (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the appointment of two new independent directors, Sarah Hofstetter, President of Profitero, Ltd., and Erica Mann, former President and Head of Bayer's Consumer Health Division, to the Company's Board of Directors (the "Board"). Additionally, Jeffrey Smith, Managing Member, Chief Executive Officer and Chief Investment Officer of Starboard Value LP (together with certain of its affiliates, "Starboard") will join the Board. All three appointments are effective immediately. "We are pleased to welcome Sarah, Erica and Jeff as

      3/5/25 8:05:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Announces Board Changes with Two New Independent Directors

      Kathleen Pawlus, Retired Partner and Global Assurance Chief Financial Officer and Chief Operating Officer at EY, and Kirk Perry, Circana President and CEO and Former Procter & Gamble and Google Executive, to Join the Board of Directors Current Johnson & Johnson Executives to Step Down from Kenvue Board of Directors Kenvue Inc. ("Kenvue" or the "Company") (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the implementation of a Board of Directors ("the Board") succession process, in line with the Company's commitment to best-in-class corporate governance and independent Board oversight. Appointment of Two New Independent Directors to the Boa

      7/31/24 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary